Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with -$6.2 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Net Income towards Common Stockholders rose 57.55% year-over-year to -$6.2 million, compared with a TTM value of -$27.3 million through Dec 2019, up 55.56%, and an annual FY2024 reading of -$90.9 million, down 117.66% over the prior year.
  • Net Income towards Common Stockholders was -$6.2 million for Q4 2019 at Larimar Therapeutics, up from -$12.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.9 million in Q2 2019 and bottomed at -$23.2 million in Q4 2015.
  • Average Net Income towards Common Stockholders over 5 years is -$13.6 million, with a median of -$14.0 million recorded in 2015.
  • The sharpest move saw Net Income towards Common Stockholders crashed 198.91% in 2015, then skyrocketed 131.26% in 2019.
  • Year by year, Net Income towards Common Stockholders stood at -$23.2 million in 2015, then skyrocketed by 54.95% to -$10.4 million in 2016, then fell by 25.35% to -$13.1 million in 2017, then decreased by 11.35% to -$14.6 million in 2018, then skyrocketed by 57.55% to -$6.2 million in 2019.
  • Business Quant data shows Net Income towards Common Stockholders for LRMR at -$6.2 million in Q4 2019, -$12.9 million in Q3 2019, and $4.9 million in Q2 2019.